The company's HCCscreen assay will be used in a liver cancer screening public health initiative, generating real-world data on the test's clinical validity and impact.
The next-generation sequencing-based panel comprises more than 50 genes and disorders known to cause hereditary anemias, such as pyruvate kinase deficiency.
The RT-PCR-based test was first authorized earlier this year for the detection of SARS-CoV-2 nucleic acid in specimens collected by a healthcare provider.
